Lake Street analyst Chad Messer lowered the firm’s price target on OS Therapies (OSTX) to $17 from $18 and keeps a Buy rating on the shares. The firm, which notes that the company incurred some significant one-time regulatory expenses during the quarter, forecasts a substantially reduced burn for Q4 and into 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX:
- OS Therapies Reports Increased Losses Amid Rising R&D Costs
- OSTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OS Therapies Approves Key Proposals at Annual Meeting
- OS Therapies Releases Investor Presentation for Stakeholders
- Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2